On 11 November 2026 the SkinSenseDiary catalogue counted 15 products with at least one variant whose ingredient list names Squalene. Squalene is an unsaturated C30 triterpene (C30H50), used as an emollient. The CIR Expert Panel concluded in 1982 that squalene is safe as a cosmetic ingredient in the present practices of use and concentration described in that report. The Panel did not reopen that assessment in 2001 or in 2019. Fiume and colleagues published the reaffirmation in 2023. Squalane is a different ingredient: the hydrogenated, more oxidation-stable form.
Squalene (INCI: Squalene, CAS 111-02-4, EC 203-826-1) is a C30 triterpene hydrocarbon, C30H50, with six double bonds. The catalogue lists the functions emollient and skin conditioning. Those are function labels for a formula. They are not a claim that the ingredient treats acne, pigment, or wrinkles. This page is about topical cosmetic use.
Squalene is not squalane. Squalene is the unsaturated C30 triterpene. Squalane (CAS 111-01-3) is the hydrogenated, saturated hydrocarbon, C30H62, and it is the more oxidation-stable of the two. The names differ by one letter, and many searches for one land on the other. A product that lists Squalane does not, by that name, contain Squalene.
The 1982 CIR report describes squalene as the principal hydrocarbon of human surface lipids: up to 11% of total surface fat, and about 5% of adult skin-surface sebum, in the figures that report gives. The same report says it is found in large amounts in shark-liver oil and in smaller amounts in olive oil, wheat-germ oil, rice-bran oil, and yeast. Manufacture in that report is molecular distillation of shark-liver oil. That account of manufacture is historical. Gohil and colleagues (Frontiers in Bioengineering and Biotechnology, 2019) describe olive oil as a plant source used for commercial recovery of squalene, and describe yeasts, including Saccharomyces cerevisiae, and other microbes as organisms that produce squalene and are developed as fermentation sources. The same review says many microbial yields are not at the level shark-liver oil has supplied. The 2019 CIR packet describes fermentable sugars as a route to squalane, the hydrogenated form, not as another name for squalene.
The primary published statement of the current CIR conclusion is Fiume and colleagues, “Squalane and Squalene,” International Journal of Toxicology 2023;42(3_suppl):107S–109S. The Panel reviewed studies available since 1982, with updated product types and concentrations, and confirmed that squalane and squalene are safe as cosmetic ingredients in the practices of use and concentration described in that report. The 1982 conclusion, kept there, was that both are safe as cosmetic ingredients in the present practices of use and concentration described in the 1982 report. In 2001 the Panel did not reopen the assessment. The June 2019 re-review summary again did not reopen it, and reaffirmed the conclusion against its Table 1. The 2023 paper publishes that reaffirmation. Table 1 gives an FDA VCRP frequency of 527 squalene formulations in 2019, up from 29 in 2001, and a 2018 industry-survey maximum of 1.2%, down from 10% in 2001. Those figures are not this catalogue’s 15 products.
The catalogue lists an emollient function. An emollient softens and smooths the skin surface. That is a formulation role. It is not a measured treatment effect for a named skin disease.
The catalogue lists skin conditioning. That is a label for how a formula is meant to leave the skin feeling. The amount in a given product is not on the INCI list.
Because squalene still has double bonds, it oxidises more readily than squalane. That is why many leave-on oils use the hydrogenated name. The two are not substitutes on a label.
Where it shows up: among the 15 catalogue products, lip products, hair oils, creams, an eyebrow pencil, concealer palettes, an exfoliator, and foot creams. It is an emollient on the ingredient list. It is not established as a treatment for a specific skin condition. A person who already reacts to a product has to read the whole list, not this one name.
Squalene and squalane are compared here on what each molecule is, how oxidation differs, and what the label name means. Many products sold as squalane are searched for as squalene.
| Squalene | Squalane | |
|---|---|---|
| What it is | The unsaturated C30 triterpene, C30H50, six double bonds. CAS 111-02-4. | The hydrogenated, saturated hydrocarbon, C30H62. CAS 111-01-3. The more oxidation-stable form. |
| On a label | The INCI name is Squalene. 角鯊烯 / 角鲨烯. | The INCI name is Squalane. 角鯊烷 / 角鲨烷. One letter is a different ingredient. |
| Oxidation | The double bonds can oxidise. Squalene monohydroperoxide is a separate material, discussed under safety. That research is not a comedogenicity rating for a cosmetic jar of squalene. | Hydrogenation removes those double bonds. The squalane page is the page for that ingredient. |
The EU CosIng entry for Squalene, ref. 78861, was read on 11 November 2026. The entry record is dated 14 November 2024. On that record the status is Active and the version is 1. The functions listed are skin conditioning – emollient, hair conditioning, and solvent. A CosIng listing names functions. It is not an approval, and it is not evidence about safety. The chemical name on the entry is 2,6,10,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaene. The entry lists CAS 111-02-4 and CAS 7683-64-9, and EC 203-826-1. It describes squalene as an unsaturated branched-chain isoprenoid hydrocarbon found in fish and plant oils.
Squalene, as a named molecule, has no entry of its own in the Annexes to Regulation (EC) No 1223/2009. That is not the same as saying every raw material that can supply it is unrestricted. Annex II, entry 419, prohibits Category 1 material and Category 2 material as defined in Articles 4 and 5 of Regulation (EC) No 1774/2002, and ingredients derived from that material. EUR-Lex records that Regulation (EC) No 1774/2002 was repealed by Regulation (EC) No 1069/2009. The CosIng note on this entry says to consider whether entry 419 applies, records that replacement, and points to Articles 8 and 9 of Regulation (EC) No 1069/2009 for Category 1 and Category 2 material. That prohibition can concern some animal-derived raw material. It is not a ban on the squalene molecule, and it does not, by itself, judge a plant-oil or fermentation grade.
The CIR conclusion and this rating are different things. Fiume and colleagues (2023) confirmed the conclusion first reached in 1982, and not reopened in 2001 or 2019: squalene is safe as a cosmetic ingredient in the practices of use and concentration described in the assessment. That is a text conclusion.
The known hazard signals are also separate. They are the aspiration statement H304, positive animal sensitisation tests, and studies of oxidised squalene. They are set out below. They are not a measure of risk from ordinary topical use of a finished cosmetic.
On this site, 1 is the low end of the hazard signal and 10 is the high end. A rating in the band 1–2 is a low hazard signal. A rating in the band 7–8 is a high hazard signal from a serious statement. The number is not a measure of the risk of using a particular product. How our hazard-signal rating works.
The number in the circle is this site’s hazard-signal rating. For squalene it comes from the list of common emollients, so H304, the animal sensitisation tests, and the oxidation studies did not set it. It is a rule-based classification. It is not a quantitative risk assessment, and it must not be read as a 20% risk. It is not a judgement on any single product.
Fiume and colleagues (International Journal of Toxicology, 2023) is the published CIR re-review. It confirms that squalane and squalene are safe as cosmetic ingredients in the practices of use and concentration described in that report. The 1982 final report reached that conclusion for the practices of use and concentration described then. The Panel did not reopen the assessment in 2001. The June 2019 re-review summary again did not reopen it, and reaffirmed the conclusion against Table 1. The 2023 paper publishes that reaffirmation. Table 1 is the scope: 527 VCRP uses in 2019, and a 2018 maximum of 1.2%. The wording is a text conclusion. It is not a numeric level, and it is not this site’s hazard-signal rating.
CIR says it is funded by the Personal Care Products Council, and that CIR, the Expert Panel for Cosmetic Ingredient Safety, and the review process are independent from the Council and the cosmetics industry. The US FDA describes CIR as an industry-funded panel of scientific and medical experts. The FDA says it participates in CIR meetings but does not vote, that it may agree or disagree with CIR conclusions, and that it takes CIR reviews into consideration when it evaluates cosmetic ingredient safety.
Irritation, becoming sensitised, and reacting again after a person is already sensitised are different events. Immediate hypersensitivity is a different event again. The 1982 report says both compounds were non-irritant to rabbit skin and eye at 100%, and that formulations containing squalene were not significant human skin irritants or sensitizers in the tests it summarised. A 72-hour contact test of pure squalene, in an unspecified number of people, reported no detectable effect on skin or hair. That is an old irritation-style test, not a count of clinical allergy.
The 2019 summary says new studies indicated there could be sensitisation potential, and that there is no significant clinical evidence of sensitisation. The Panel stated a lack of case reports despite the higher use frequency. This page does not turn that statement into a counted series of published cases, and it does not call reactions rare. Kreiling and colleagues (Food and Chemical Toxicology, 2008) reported a positive local lymph node assay, with a dose-response, and sensitisation reactions in 2 of 10 guinea pigs in a maximisation test. Those are predictive animal tests for contact sensitisation. They are not patch tests in dermatitis patients, and they are not evidence about which exposure route dominates in people. In the local lymph node assay the concentrations were 10%, 25%, and 50%. In the guinea pig maximisation test, topical induction and challenge used undiluted material, after an intradermal induction at 5%. Those concentrations are not the 1.2% maximum in the 2018 use survey. A positive result at those higher concentrations is a sensitisation signal from the test. It is not the same exposure as the survey maximum, and it is not a result this page sets aside because the survey figure is lower. Kreiling and colleagues set out to test whether chemicals with unsaturated carbon–carbon double bonds may give a higher number of unspecific, false-positive results in the local lymph node assay than in the guinea pig maximisation test. Seven substances, including squalene, were clearly positive in the lymph node assay and, on that result, would require labelling as a skin sensitiser. On the guinea pig results, under Directive 67/548/EEC as that paper applies it, only undecylenic acid would have required classification and labelling as a skin sensitiser. Linoleic acid was inconclusive. The other seven substances, squalene among them, would not have required that labelling. The authors conclude that the suitability of the lymph node assay for unsaturated compounds of this structural kind should be considered carefully. That context does not set aside the positive animal findings. The fuller protocol is under Further reading. A positive predictive test and a clinical reaction in someone who is already sensitised are different outcomes.
Chiba and colleagues (Journal of Toxicological Sciences, 2000) applied squalene monohydroperoxide, made by UVA irradiation of squalene, to rabbit ear skin. That peroxide induced comedones. Squalene itself, and reduced squalene hydroxide, were lower in that assay than the peroxide. This is an animal experiment on oxidised squalene. It is not a rate of clogged pores in people using a cosmetic that lists squalene, and it is not a finding that topical cosmetic squalene and oxidised sebum are the same material. The 2019 CIR summary cites this paper and still reaffirmed the cosmetic conclusion.
H304: H304 is reported in ECHA’s Classification and Labelling Inventory, in the summary PubChem gives for company notifications, and on the EDQM safety data sheet for Squalene CRS (catalogue code Y0002131, SDS product code 201900021, version 2.0, revised 6 September 2024), which classifies it as aspiration hazard Category 1, H304. The shares of those notifications are under Further reading. This page does not identify which notification or sheet its hazard line was taken from. H304 means may be fatal if swallowed and enters airways. It concerns swallowing followed by entry into the airways. It is not a skin-irritation statement and not a skin-sensitisation statement, and it should not be read as a measure of risk from normal topical cosmetic use. Article 1(5) of Regulation (EC) No 1272/2008, in the consolidated text of 1 May 2020, says the CLP Regulation shall not apply to substances and mixtures in the finished state, intended for the final user, including cosmetic products as defined in Directive 76/768/EEC. An ingredient’s H304 does not carry over as a CLP label on a cream or lipstick supplied to an end user. H304 is not what sets the hazard-signal rating.
Use levels in the 2019 table: Table 1 of the June 2019 summary gives squalene a 2018 concentration range of 0.004–1.2%. Leave-on is 0.0045–0.7%. Rinse-off is 0.004–1.2%. Dermal contact is 0.004–0.7%. Hair, non-coloring, is 0.07–1.2%. VCRP frequency in 2019 is 527 uses (300 leave-on, 215 rinse-off), against 29 uses in 2001, when the reported maximum was 10%. The 2018 figures are unpublished data submitted by the Personal Care Products Council on 1 June 2018. They are category survey values, not the percentage in a reader’s product, and not a legal limit. The 1982 report had described a much wider historical band, up to above 50% in some formulations of that era. The 2019 reaffirmation points at Table 1, not at that older band.
Neat squalene and hair in animal tests: The 1982 report describes a reversible loss of hair after neat squalene in rabbits and in three of four guinea pigs, and no such loss in the mice in that experiment. A small volunteer series, with little detail reported, did not describe hair loss after daily application for six weeks. That animal finding is not a rate for cosmetics at the 2018 survey concentrations. The 2019 summary does not reopen the assessment on account of it.
Oxidation: Squalene’s double bonds are why squalane, the hydrogenated form, is the more shelf-stable cosmetic hydrocarbon. Oxidation studies of squalene monohydroperoxide belong to that peroxide. They do not, by themselves, rate every product that lists the parent ingredient. Ekanayake Mudiyanselage and colleagues (Journal of Investigative Dermatology, 2003) reported squalene monohydroperoxide isomers in human sebum after ultraviolet A, both in sebum irradiated in the laboratory and on skin. Curpen and colleagues (Skin Research and Technology, 2020) reported that ozone exposure of human skin lowered squalene in sebum and raised squalene monohydroperoxide. Neither result is a rate of breakouts for a person using a cosmetic that lists squalene.
Further reading: In the local lymph node assay summarised for the 2019 packet, groups of five mice received 25 µl of squalene at 10%, 25%, and 50% in acetone/olive oil (3:1), once a day for three days on the ear. The assay was positive, with a dose-response. In the guinea pig maximisation test, 10 animals were induced intradermally with 5% squalene, then induced and challenged topically with the undiluted material. Two animals showed sensitisation reactions. Kreiling et al., 2008. In the rabbit-ear comedogenicity assay, comedone formation was described at about 2 mmol/L squalene monohydroperoxide, about 39 µg/cm². Squalene itself scored lower than that peroxide. Chiba et al., 2000. A cream containing 1% squalene, also containing other ingredients, produced no erythema in 16 women after a 24-hour patch or in 36 women using it twice daily for 21 days, as the CIR packet summarises Filipovic et al., Vojnosanitetski Pregled, 2016. That is an irritation observation on one finished cream. The 10%, 25%, and 50% lymph-node concentrations, and the undiluted guinea pig challenge, are not the 1.2% maximum in the 2018 survey. They remain sensitisation signals from those tests. PubChem’s summary covers 314 reports from 3 notifications. It shows H304 at 73.6%, and it says the substance does not meet GHS hazard criteria for 25.5% (80 of 314 reports). PubChem states that a percentage in parentheses is the notified classification ratio from companies that provide hazard codes. Those figures are shares of notifications, not a measure of risk from a cosmetic product.
Other uses: Oral squalene capsules, and squalene-containing vaccine adjuvant emulsions such as MF59, an oil-in-water emulsion of squalene oil, are outside this page. The cosmetic assessment above is about topical use.
The 1982 report, the 2019 reaffirmation, and the 2023 paper do not tell people to avoid cosmetic squalene in pregnancy or while breastfeeding, and they do not set a cosmetic concentration just for pregnancy or breastfeeding. Not advising avoidance is not a pregnancy-specific assessment. The sources cited on this page are not enough to quantify risk from cosmetic use during pregnancy or breastfeeding. This page does not estimate that risk from a cream, a lip product, or a hair oil. Someone who is pregnant or breastfeeding and wants advice about a specific product should ask their own clinician.
Look for the INCI name Squalene. Squalane is the other ingredient. Labels in other markets may also show 角鯊烯, 角鲨烯, スクワレン, or 스쿠알렌. Those are the written Traditional Chinese and Simplified Chinese names and the Japanese (JCIA) and Korean (KCID) names. Under Regulation (EC) No 1223/2009, Article 19(1)(g), ingredients are listed in descending order of weight when they are added, and ingredients below 1% may be listed in any order after the ones at or above 1%. A position near the end does not reveal the percentage. On 11 November 2026 several catalogue products had one variant that names Squalene and another variant that names Squalane. The variant in hand is the one that matters.
The hydrogenated, more oxidation-stable form. It is a different INCI name. The comparison table is above.
A humectant. It holds water. Squalene is a hydrocarbon emollient. They do different jobs when both appear on a list.
An antioxidant that often appears in oil formulas. This page does not claim that tocopherol stops squalene oxidation in a finished product.
On 11 November 2026 the catalogue counted 15 products with at least one variant whose ingredient list names Squalene. A product is counted once. The count is a usage figure for this catalogue, not evidence of safety. The cards are a selection of those 15. Each card uses the name of the product or the variant that lists Squalene, and the kind of product that name describes. Foot creams and concealer palettes are in the count of 15 and are not on the cards.